Serum leucine-rich alpha-2 glycoprotein levels for predicting ultrasonographic findings in intestinal lesion of patients with Crohn's disease in clinical remission (SAPICL study)
Not Applicable
Recruiting
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000049228
- Lead Sponsor
- Sapporo IBD Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients whose data of Harvey-Bradshaw Index (HBI) could not be evaluated from medical records. (2) Patients whose HBI is 5 or above. (3) Patients who had underwent intestinal resection.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determining the cutoff value of LRG levels for predicting positive bowel wall thickness (BWT), focally or extensively disrupted bowel wall echo patterns, and respective superb micro-vascular imaging(SMI) grades and calculating the sensitivity and specificity.
- Secondary Outcome Measures
Name Time Method Comparison of the median LRG levels for the positive BWT, focally or extensively disrupted bowel wall echo patterns, and respective SMI grades. Proportion of patients with positive BWT, those with focally or extensively disrupted bowel wall echo pattern, and those with respective SMI grades, respectively stratified by cutoff value of LRG levels. Proportion of patients with focally or extensively disrupted bowel wall echo pattern and that with respective SMI grades, respectively stratified by BWT. Evaluating the background factors related to the LRG levels. Determining the LRG cutoff value stratified by the background factors related to LRG levels and calculating the sensitivity and specificity. Etc